2Winkler J, Thal LJ, Gage FH et al. Cholinergic strategies for Alzheimers disease[J]. J Mol Med, 1998,76(8):555-67.
3Wu K, Meyers CA, Guerra NK et al. The effects of rAAV2-mediated NGF gene delivery in adult and aged rats[J]. Mol Ther,2004,9(2):262-9.
4Massa SM, Xie Y, Longo FM. Alzheimers therapeutics: Neurotrophin small molecule mimetics[J]. J Mol Neurosci, 2002,19(1-2):107-11.
5Ishihara Y, Goto G, Miyamoto M. Central selective acetylcholinesterase inhibitor with neurotrophic activity: Structure-activity relationships of TAK-147 and related compounds[J]. Curr Med Chem,2000,7(3):341-54.
6Dechant G, Neumann H. Neurotrophins[J]. Adv Exp Med Biol,2002,513:303-34.
7Dawbarn C, Allen SJ. Neurotrophins and neurodegeneration[J].Neuropathol Appl Neurobiol, 2003,29(3):211-30.
8Bax B, Blundell TL, Murray-Rust J et al. Structure of mouse 7S NGF: A complex of nerve growth factor with four binding proteins[J].Structure,1997, 5(10):1275-85.
9Lad SP, Neet KE, Mufson EJ. Nerve growth factor: Structure, function and therapeutic implications for Alzheimers disease[J]. Curr Drug Target CNS Neurol Disord,2003,2(5):315-34.
10Mufson EJ, Ginsberg SD, Ikonomovic MD, DeKosky ST. Human cholinergic basal forebrain: Chemoanatomy and neurologic dysfunction[J]. J Chem Neuroanat,2003,26(4):233-42.
10Gao L, Li J, Qi J. Gentisides A and B, two new neuritogenic compounds from the traditional chinese medicine Gentiana rigescens Franch[ J]. Bioorg Med Chem, 2010,18(6) :2131 -4.
